Related Experiment Video
Updated: Nov 30, 2025
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
1.3K
Hyperoside Attenuates Bleomycin-Induced Pulmonary Fibrosis Development in Mice.
Jizhen Huang1, Xiang Tong1, Li Zhang1
1Department of Respiratory and Critical Care Medicine, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.
Frontiers in Pharmacology
|November 16, 2020
Summary
Hyperoside, a natural compound, effectively reduced lung fibrosis in mice by combating inflammation and oxidative stress. This suggests hyperoside as a potential new treatment for pulmonary fibrosis.
Area of Science:
- Pharmacology and Toxicology
- Respiratory Medicine
- Biochemistry
Background:
- Idiopathic pulmonary fibrosis (IPF) is a severe, progressive lung disease with no effective drug treatments.
- Hyperoside, a flavonoid glycoside, exhibits known anti-inflammatory, anti-fibrotic, and antioxidant properties.
- Exploring natural compounds like hyperoside is crucial for developing novel IPF therapies.
Purpose of the Study:
- To investigate the therapeutic potential of hyperoside in a mouse model of bleomycin-induced pulmonary fibrosis.
- To evaluate hyperoside's effects on fibrotic changes, oxidative stress, inflammation, and epithelial-mesenchymal transition (EMT) in the lungs.
Main Methods:
- Pulmonary fibrosis was induced in mice using bleomycin via intratracheal aerosol injection.
- Mice received intraperitoneal hyperoside treatment for 14 days, starting seven days post-bleomycin administration.
- Assessed lung pathology, collagen deposition, oxidative stress markers (MDA, SOD), inflammatory cytokines (TNF-α, IL-6), and EMT markers.
Main Results:
- Hyperoside treatment significantly ameliorated fibrotic pathological changes and collagen deposition in the lungs.
- Hyperoside reduced levels of malondialdehyde (MDA), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), while increasing superoxide dismutase (SOD) activity.
- Evidence suggests hyperoside inhibits epithelial-mesenchymal transition (EMT) potentially through the AKT/GSK3β pathway.
Conclusions:
- Hyperoside effectively attenuated pulmonary fibrosis in mice by mitigating oxidative stress, inflammation, and EMT.
- These findings highlight hyperoside's potential as a promising therapeutic candidate for treating pulmonary fibrosis.
- Further research into hyperoside's mechanisms and clinical efficacy is warranted.
